Chief Executive Officer, President and Chairman, Kevin Hrusovsky, will be presenting at the LEERINK Partners 7th Annual Global Healthcare Summit. The presentation will take place on Thursday, February 15, at 10:00 a.m. EST in New York City.
Business Wire | February 08, 2018
Business Wire | January 04, 2018
Chief Executive Officer, President and Chairman, Kevin Hrusovsky, will present a company overview at the 36th Annual J.P. Morgan Healthcare Conference.
Business Wire | January 02, 2018
Ultra-Sensitive Biomarker Detection System is now available in a compact size with increased workflow flexibility
BusinessWire | December 11, 2017
Quanterix Corporation (NASDAQ:QTRX), a company with a next generation, ultra-sensitive digital platform that advances precision health, today announced the closing of its initial public offering of 4,916,480 shares of common stock at a public offering price of $15.00 per share, including 641,280…
Nasdaq | December 07, 2017
Quanterix Corporation (Nasdaq:QTRX), a company with a next generation, ultra-sensitive digital platform that advances precision health, will visit the Nasdaq MarketSite in Times Square.
Business Wire | December 06, 2017
Today Quanterix announced the pricing of its initial public offering of 4,275,200 shares of its common stock at a public offering price of $15.00 per share for aggregate gross proceeds of $64,128,000. In addition, Quanterix has granted the underwriters a 30-day option to purchase up to 641,280…
Business Wire| November 27, 2017
Quanterix Corporation today announced the commencement of the initial public offering of shares of its common stock pursuant to a registration statement on Form S-1 filed with the Securities and Exchange Commission (the “Commission”).
Business Wire | November 10, 2017
New technology unlocks ultra-sensitive biomarker detection with the potential to advance the diagnosis and treatment of neurological diseases
Discussion will be led by Dr. Edward Wild and Lauren Byrne from the UCL Institute of Neurology, with introductory remarks from Kevin Hrusovsky, Executive Chairman and CEO, Quanterix
Quanterix to Launch High-Sensitivity Benchtop Instrument and Assays for Multiplex Biomarker Detection
New benchtop design and expanded assay portfolio offers researchers greater access to ultra-sensitive Simoa technology for unrivaled biomarker detection